Company: JUNS
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001641172-25-010990
Chunk: 67

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-05-15
Form: 10-Q
Item: Item 2
Chunk 67
---
2025 and March 31, 2024, we generated no revenues from product sales and reported net losses of $1,528,867 and $634,100, respectively,
and negative cash flow from operating activities of $1,063,041 and $65,165, respectively. There is substantial doubt regarding our ability
to continue as a going concern as a result of our historical recurring losses and negative cash flows from operations as well as our dependence
on financings.

Our failure to raise capital
as and when needed could have a negative impact on our financial condition and our ability to pursue our business strategies. We anticipate
that we will need to raise substantial additional capital, the requirements of which will depend on many factors, including:

    ●
    the scope, rate of progress and costs of our drug delivery, preclinical development activities, laboratory testing and clinical trials for our drug candidate;

    ●
    the number and scope of clinical programs we decide to pursue;

    ●
    the scope and costs of manufacturing development and commercial manufacturing activities;

    ●
    the extent to which we acquire or in-license other drug candidate and technologies;

    ●
    the cost, timing and outcome of regulatory review of our drug candidate;

    ●
    the cost and timing of establishing sales and marketing capabilities, if our drug candidate receives marketing approval;

    ●
    the costs of preparing, filing and prosecuting patent applications, obtaining, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims;

    ●
    our ability to establish and maintain collaborations on favorable terms, if at all;

    ●
    our efforts to enhance operational systems and our ability to attract, hire and retain qualified personnel, including personnel to support the development of our drug candidate;

    ●
    the costs associated with being a public company; and

    ●
    the cost associated with commercializing our drug candidate, if it receives marketing approval.

26

If we raise additional funds
by issuing equity securities, our stockholders may experience dilution. Any future debt financing into which we enter may impose upon
us additional covenants that restrict our operations, including limitations on our ability to incur liens or additional debt, pay dividends,
repurchase our common stock, make certain investments and engage in certain merger, consolidation or asset sale transactions. Any debt
financing or additional equity that we raise may contain terms that are not favorable to us or our stockholders. If we are unable to raise
additional funds when needed, we may be